{"id":"W2947494310","doi":"10.1200/jco.2019.37.15_suppl.3094","title":"A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Medicine; Tolerability; Toxicity; Pharmacokinetics; Dosing; Internal medicine; Prostate cancer; Adverse effect; Phases of clinical research; Gastroenterology; Urology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001107464,0.0001248883,0.0008988468,0.00009494589,0.00001803262,0.000004143049,0.0002104938,0.0003109244,0.00003559079],"category_scores_gemma":[0.0007496083,0.0001004296,0.0002024152,0.0001151504,0.0001101552,0.000007449354,0.00008508707,0.0003952987,9.961034e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007849287,"about_ca_system_score_gemma":0.001505538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001035372,"about_ca_topic_score_gemma":0.003425244,"domain_scores_codex":[0.9977227,0.0001205427,0.001568696,0.0002191632,0.0001560511,0.0002128173],"domain_scores_gemma":[0.9979227,0.0003331531,0.001236756,0.000204652,0.0001766177,0.0001261822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5264957,0.02267762,0.1582586,0.0001853071,0.0005193412,0.0005133762,0.0004140699,0.01158334,0.1469607,0.0004125746,0.00339712,0.1285823],"study_design_scores_gemma":[0.5095701,0.2884444,0.02621174,0.0003886033,0.0001207915,0.0000476753,0.0001840801,0.0001133323,0.02392955,0.0003421508,0.150201,0.0004465122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964784,0.0006938605,0.0000152083,0.0006252681,0.001135983,0.0003039115,0.000009955867,9.404482e-7,0.0007364205],"genre_scores_gemma":[0.9963515,0.001891517,0.0004248939,0.0003356073,0.0008896456,0.0000100145,0.000004621258,0.00001508017,0.00007709818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2657668,"threshold_uncertainty_score":0.4095401,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03546129956307053,"score_gpt":0.4211166670666374,"score_spread":0.3856553675035669,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}